source
- Gilead and Merck provide HIV data; Dimension Capital announces $800M fundGilead and Merck’s HIV data: The duo will present more detailed results of the Phase 3 trials of their once-weekly oral HIV treatment regimen at AIDS 2026, one of the largest ...Endpoints · 8d ago↗ source
- Agios’ second shot at sickle cell disease falls shortAgios said it is dropping a next-generation sickle cell disease drug after lackluster results from a mid-stage trial. The drug, known as tebapivat, represented Agios’ second shot at the disease, an…Endpoints · 8d ago↗ source
- Notes from a peptide meetupWith an FDA advisory committee set to decide this week whether it recommends that several popular peptides be reclassified, I wanted to learn more. Cue a last-minute ticket purchase to ...Endpoints